Test Price
2,800 AED✅ Home Collection Available
SLC29A3 Gene Histiocytosis‑Lymphadenopathy Plus Syndrome Genetic Test in UAE
Executive Summary & Core Metrics
✦ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing.
✦ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM – 11 PM).
✦ Clinical Guidance: Telephonic Post-Test Clinical Guidance with a DHA-Licensed Genetic Counsellor included.
✦ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced Next‑Generation Sequencing (NGS) test screens the entire coding sequence of the SLC29A3 gene for pathogenic variants linked to histiocytosis‑lymphadenopathy plus syndrome (H syndrome), a multisystemic autosomal recessive disorder. Results inform precise dermatologic, immunologic, and osteologic management and help personalize future surveillance for at‑risk family members.
| Parameter | Our Test (Premium NGS) | Closest Alternative |
|---|---|---|
| Precision | Full‑gene sequencing with 99.9% analytical sensitivity | Sanger sequencing of selected exons (misses deep intronic / regulatory variants) |
| Methodology | Illumina® NGS platform with CNV detection | Capillary electrophoresis; limited variant calling |
| Turnaround | 3–4 weeks (expedited reporting available) | 4–8 weeks typical |
*Alternative refers to targeted Sanger sequencing of selected regions only; does not represent any specific laboratory in the UAE.
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA License: 9294403) notes: “Genetic findings must always be correlated with the patient’s clinical picture and family history. A positive mutation does not guarantee disease manifestation, and even a negative result should not override a strong clinical suspicion. All decisions—especially medication adjustments—must remain within the treating physician’s direct guidance.”
Medication Advisory
⛔ Medication Warning
Do not discontinue or modify any prescribed medication (including immunosuppressants, hormonal therapies, or anti‑inflammatory drugs) without consulting your doctor.
Patient Safety: Exclusion Criteria & Emergency Red Flags
- Exclusion criteria: Recent blood transfusion (<3 weeks) may cause donor DNA interference; test is not validated for somatic mutation analysis in tumours or prenatal diagnosis without prior genetic counselling.
- ER red flags: Unexplained persistent fever >38°C, rapidly enlarging lymph nodes, severe bone pain, or signs of airway compromise require immediate emergency evaluation—do not delay for genetic results.
- Paediatric note: For minors, testing must comply with Federal Decree-Law No. 4 of 2016 on Medical Liability and the UAE Child Protection Law; parental consent and genetic counselling are mandatory.
- Pregnant or breastfeeding individuals should discuss the test’s relevance with a maternal‑fetal medicine specialist.
All samples are processed in a CLIA‑accredited, ISO 9001:2015 certified laboratory (Cert: INT/EGQ/2509DA/3139). Data handled in full compliance with UAE PDPL.
Patient FAQ & Clinical Guidance
1. What does this NGS test detect in the SLC29A3 gene?
This test sequences all SLC29A3 coding exons to identify disease‑causing mutations linked to histiocytosis‑lymphadenopathy plus syndrome with 99.9% accuracy. The analysis covers single nucleotide variants, small insertions/deletions, and copy number variations using advanced bioinformatics. Results guide precise dermatology, immunology, and orthopaedic follow‑up.
2. How should I prepare for the sample collection?
Fasting is not required; simply provide a blood sample, extracted DNA, or a single drop on an FTA card with clinical history. A genetic counselling session and pedigree chart are mandatory before testing to ensure appropriate selection. Our team arranges phlebotomy at your doorstep between 8 AM and 11 PM.
3. What do positive and negative results mean for family members?
A positive result confirms biallelic mutations, enabling carrier testing of parents and siblings; a negative result excludes the known familial variant but not all risks. Cascade screening is recommended and can be coordinated through our genetic counsellors. All results remain confidential under UAE data privacy laws.
UAE Regulatory & Data Privacy Adherence
This genetic test is performed in full compliance with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL)
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
- Federal Decree-Law No. 4 of 2016 on Medical Liability
All patient data are encrypted, access‑controlled, and stored within the UAE. You have the right to access, rectify, or delete your personal data at any time. For any privacy concerns, contact our Data Protection Officer.
Clinical & Logistical Metadata
| Test Name | SLC29A3 Gene Histiocytosis‑Lymphadenopathy Plus Syndrome Genetic Test (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks (expedited reporting available) |
| Sample Type / Matrix | Whole Blood (peripheral) or extracted DNA; home phlebotomy available |
| Methodology Used | Next‑Generation Sequencing (NGS) on Illumina® platform with CNV detection |
| ICD-10-CM Code | D76.3 |
| LOINC Code | 92726-2 |
| DHA Facility License & Lab Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians